Advertisement

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: The Alzhemedtm (Tramiprosate) experience

  • D. Saumier
  • P. S. Aisen
  • S. Gauthier
  • B. Vellas
  • S. H. Ferris
  • A. Duong
  • J. Suhy
  • J. Oh
  • W. Lau
  • D. Garceau
  • D. Haine
  • J. Sampalis
The Alzhemed™ (Tramiprosate) Experience

Keywords

Alzheimer Disease Memantine Disease Modification Homotaurine Hippocampus Volume Change 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gandy S. The role of cerebral amyloid accumulation in common forms of Alzheimer disease. Journal of Clinical Investigation. 2005; 115: 1121–1129.PubMedGoogle Scholar
  2. 2.
    Caniveri L, Abramov A, & Duchen MR. Toxicity of amyloid B peptide: Tales of calcium, mitochondria, and oxidative stress. Neurochemical Research, 2004; 29: 637–650.CrossRefGoogle Scholar
  3. 3.
    Sampaio C. Alzheimer’s disease: Disease modifying trials. Where are we? Where do we need to go? A reflective paper. Journal of Nutrition, Health and Aging. 2006; 10(2): 113–115.Google Scholar
  4. 4.
    Katz R. Biomarkers and Surrogate Markers: An FDA perspective. NeuroRx. 2004; 1: 189–195.PubMedCrossRefGoogle Scholar
  5. 5.
    Goshe KM, Mortimer JA, Smith CD, et al. Hippocampal volume as an index of Azheimer neuropathology: findings from the Nun study. Neurology. 2002; 58: 1476–1482Google Scholar
  6. 6.
    Haroutunian V, Perl, DP, Purohit, DP, et al. Regional distribution of neuritic plaques in the non-demented elderly and subjects with very mild Alzheimer disease. Archives of Neurology. 1998; 1185–1191.Google Scholar
  7. 7.
    Convit A, de Leon MJ, Golomb J, et al. Hippocampal atrophy in early Alzheimer’s disease: anatomic specificity and validation. Psychiatric Quarterly. 1993; 64: 371–387.PubMedCrossRefGoogle Scholar
  8. 8.
    Csernansky JG, Wang L, Joshi S. et al. Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. Neurology. 2000; 55: 1636–1643.PubMedGoogle Scholar
  9. 9.
    Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiology of Aging. 2001; 22: 747–754.PubMedCrossRefGoogle Scholar
  10. 10.
    Du AT, Schuff N, Amend D. et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 2001; 71: 441–447.CrossRefGoogle Scholar
  11. 11.
    Du AT, Schuff N, Kramer JH et al. Higher Atrophy Rate of Entorhinal Cortex than Hippocampus in AD. Neurology. 2004; 62: 422–427.PubMedGoogle Scholar
  12. 12.
    Krasuski JS, Alexander GE, Horwitz B. et al. Relation of medial temporal lobe volumes to age and memory function in non-demented adults with Down’s syndrome: implications for the prodromal phase of Alzheimer’s disease. American Journal of Psychiatry. 2002; 159: 74–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Mega MS, Small, GW, Xu ML, et al. Hippocampal atrophy in persons with age-associated memory impairment: volumetry within a common space. Psychosomatic Medicine. 2002; 64; 487–492.PubMedGoogle Scholar
  14. 14.
    Mu Q, Xie J, Wen Z, et al. A quantitative MR study of the hippocampal formation, the amygdale, and the temporal horn of the lateral ventricle in healthy subjects 40 to 90 years of age. American Journal of Neuroradiology. 1999; 20: 207–211.PubMedGoogle Scholar
  15. 15.
    Xu Y, Jack CRJ, O’Brien PC, et al. Usefulness of MRI measures of entrorhinal versus hippocampus in AD. Neurology. 2000; 14: 531–545.Google Scholar
  16. 16.
    Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiology of Aging. 2007; 28: 537–547.PubMedCrossRefGoogle Scholar
  17. 17.
    Azzi M, Morissette C, Fallon L, et al. Involvement of both GABA-dependent and - independent pathways in tramiprosate neuroprotective effects against amyloid-beta toxicity. 8th International Conference AD/PD, Salzburg, Austria, March 14–18. 2007.Google Scholar
  18. 18.
    Aisen P, Saumier D, Briand R, et al. A Phase II study targeting amyloid- with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006; 67: 1757–1763.PubMedCrossRefGoogle Scholar
  19. 19.
    Hsu YY, Schuff N, Du AT, et al, Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. Journal of Magnetic Reson ance Imaging. 2002; 16:305–310.CrossRefGoogle Scholar
  20. 20.
    Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Disease and Associated Disorders. 2006; 20: 6–15PubMedCrossRefGoogle Scholar
  21. 21.
    Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. American Journal of Psychiatry. 1994; 151: 390–396.PubMedGoogle Scholar
  22. 22.
    Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurology. 2007; 6: 734–746.PubMedCrossRefGoogle Scholar
  23. 23.
    Laakso MP, Soininen H, Partanen K, et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer’s disease: correlation with memory functions. Journal of Neural Transmission. Parkinson’s Disease and Dementia Section. 1995; 9: 73–86.PubMedCrossRefGoogle Scholar

Copyright information

© Serdi and Springer Verlag France 2009

Authors and Affiliations

  • D. Saumier
    • 1
  • P. S. Aisen
    • 2
  • S. Gauthier
    • 3
  • B. Vellas
    • 4
  • S. H. Ferris
    • 5
    • 6
  • A. Duong
    • 1
  • J. Suhy
    • 7
  • J. Oh
    • 7
  • W. Lau
    • 7
  • D. Garceau
    • 8
  • D. Haine
    • 9
  • J. Sampalis
    • 10
  1. 1.BELLUS Health Inc.LavalCanada
  2. 2.University of California, San DiegoLa JollaUSA
  3. 3.McGill Ctr / Studies in AgingVerdunCanada
  4. 4.Gérontopole, Pôle GériatrieCentre Hospitalier Universitaire, Alzheimer Disease Research and Clinical Center, University of ToulouseToulouseFrance
  5. 5.New York University School of MedicineNew YorkUSA
  6. 6.Nathan Kline InstituteOrangeburgUSA
  7. 7.Synarc Inc.San FranciscoUSA
  8. 8.OVOS Natural Health Inc.LavalCanada
  9. 9.JSS Medical ResearchWestmountCanada
  10. 10.Division of Clinical EpidemiologyMcGill University, Research Institute of the McGill University Health Centre, Royal Victoria HospitalMontrealCanada

Personalised recommendations